Infectious Disease and Microbiology – Human T-Lymphotropic Viruses (HTLV-1 and HTLV-2)

Overview

Human T-lymphotropic viruses HTLV-1 and HTLV-2 are enveloped retroviruses with single-stranded positive-sense RNA genomes. They infect human T lymphocytes and can establish lifelong infection.

HTLV-1 is clearly associated with several important diseases, particularly adult T-cell leukemia/lymphoma (ATLL) and HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP). By contrast, HTLV-2 has not been firmly linked to a comparable specific malignant disease.

Classification

Viruses: HTLV-1 and HTLV-2

Group: Human T-lymphotropic viruses

Family: Retroviridae

Type: Retroviruses

The historical term “human T-lymphocyte virus” is still commonly used, but “human T-lymphotropic virus” is the standard modern wording.

Microbiologic Characteristics

HTLV-1 and HTLV-2 are:

• Single-stranded positive-sense RNA viruses

• Enveloped

• Retroviruses

• Capable of reverse transcription

• Able to integrate viral DNA into the host-cell genome

Like other retroviruses, they use:

Reverse transcriptase

to convert viral RNA into DNA.

Viral Replication

The general retroviral sequence is:

Viral RNA

↓

Reverse transcription

↓

Proviral DNA

↓

Integration into host genome

↓

Persistent infection of host cells

This ability to integrate into host DNA contributes to lifelong infection.

Incubation and Latency

A precise incubation period is:

Not well defined

For HTLV-1–associated diseases, the interval between infection and clinical disease can be:

Many years to decades

Only a minority of infected individuals develop major HTLV-1–associated complications.

Epidemiology

HTLV infection occurs in multiple regions worldwide.

HTLV-1 is particularly endemic in:

• Southwestern Japan

• The Caribbean

• Parts of sub-Saharan Africa

• Parts of South America

• Other geographically clustered populations

The source specifically highlights high HTLV-1 seropositivity in:

Southeastern Japanese islands and the Caribbean basin

HTLV-2 Epidemiology

HTLV-2 has been detected in several populations and has historically had a strong association with:

Injection drug use

The virus has also been identified in certain indigenous populations.

Transmission

HTLV can be transmitted through infected lymphocytes in:

• Sexual contact

• Blood exposure

• Sharing contaminated injection equipment

• Mother-to-child transmission

Mother-to-child transmission occurs especially through:

Breastfeeding

Prevention Principle

The source states that prevention resembles that used for HIV.

Important preventive measures therefore include:

• Safer-sex practices

• Avoidance of shared needles or injection equipment

• Screening of blood products where applicable

• Prevention of mother-to-child transmission in appropriate settings

HTLV-1 Infection

Major Disease Associations

HTLV-1 is associated with:

Adult T-cell leukemia/lymphoma

and

HTLV-1–associated myelopathy/tropical spastic paraparesis

Other inflammatory and infectious associations can also occur.

Adult T-Cell Leukemia/Lymphoma

Major Malignancy

One of the classic complications of HTLV-1 is:

Adult T-cell leukemia/lymphoma (ATLL)

This is a malignancy of mature T lymphocytes.

Clinical Features

ATLL may present with:

• Lymphadenopathy

• Skin lesions

• Hepatosplenomegaly

• Circulating abnormal T cells

• Immunosuppression

• Opportunistic infections

A particularly important metabolic complication is:

Hypercalcemia

High-Yield ATLL Pattern

Adult from an HTLV-1 endemic region

• ●

T-cell malignancy

• ●

Hypercalcemia

• ●

Characteristic abnormal lymphocytes

→ Think HTLV-1–associated adult T-cell leukemia/lymphoma

Flower Cells

Peripheral blood may show atypical lymphocytes with multilobulated nuclei classically called:

“Flower cells”

This is a memorable hematologic association with ATLL.

HTLV-1–Associated Myelopathy

HAM/TSP

HTLV-1 can cause a chronic progressive neurologic syndrome known as:

HTLV-1–associated myelopathy

or:

Tropical spastic paraparesis

abbreviated:

HAM/TSP

Clinical Manifestations

HAM/TSP typically causes:

• Slowly progressive weakness of both legs

• Spastic paraparesis

• Hyperreflexia

• Gait impairment

• Urinary dysfunction

• Sensory symptoms of variable severity

The condition usually evolves gradually rather than as an acute myelitis.

High-Yield Neurologic Pattern

HTLV-1 exposure

• ●

Slowly progressive bilateral leg weakness

• ●

Spasticity and hyperreflexia

• ●

Bladder dysfunction

→ Think HAM/TSP

Infective Dermatitis

The source lists:

Jamaican infectious dermatitis

This is more commonly referred to as:

HTLV-1–associated infective dermatitis

It is a chronic relapsing dermatitis, particularly recognized in children in HTLV-1 endemic areas.

Strongyloides Association

HTLV-1 infection is also clinically important because it is associated with increased susceptibility to severe or persistent:

Strongyloides stercoralis infection

This interaction can complicate treatment and increase the risk of severe strongyloidiasis.

HTLV-2

Clinical Significance

The source states that:

No disease has been conclusively causally associated with HTLV-2

HTLV-2 was initially isolated from patients with hairy-cell leukemia, but this association was not established as causal.

HTLV-2 Today

HTLV-2 infection is generally considered less pathogenic than HTLV-1.

Some neurologic or inflammatory associations have been reported, but there is no classic disease syndrome equivalent to:

HTLV-1 → ATLL or HAM/TSP

Diagnosis

The source lists:

• Cell culture

• Serology

• Antigen detection

In modern practice, diagnosis is primarily based on:

Serologic testing

with confirmatory testing when required.

Serology

Screening tests detect:

Antibodies against HTLV

Positive screening results may require confirmatory assays to distinguish:

HTLV-1

from:

HTLV-2

Molecular Testing

PCR can detect:

Proviral HTLV DNA

and may help confirm infection or distinguish HTLV-1 from HTLV-2 in selected circumstances.

Treatment

HTLV Infection Itself

The source describes treatment as:

Symptomatic

There is no standard therapy that reliably eradicates integrated HTLV infection from the body.

Management therefore focuses largely on treating:

HTLV-associated diseases

rather than eliminating the latent virus itself.

Adult T-Cell Leukemia/Lymphoma Treatment

Management of ATLL depends on its clinical subtype and severity and may involve:

• Antineoplastic chemotherapy

• Antiviral-based approaches in selected forms

• Targeted therapy

• Hematopoietic stem-cell transplantation in selected patients

This requires specialist hematology/oncology management.

HAM/TSP Treatment

Treatment is generally aimed at:

Reducing inflammation and controlling symptoms

No therapy reliably reverses established neurologic damage in all patients.

Supportive treatment may include:

• Management of spasticity

• Physical rehabilitation

• Bladder management

• Pain management

Prevention

Because HTLV spreads through infected lymphocytes, preventive strategies resemble those used for other blood-borne and sexually transmitted retroviruses.

Important measures include:

• Safer sexual practices

• Avoiding shared injection equipment

• Appropriate blood-donor screening

• Prevention of mother-to-child transmission

Breastfeeding and Transmission

Prolonged breastfeeding is an important route of:

HTLV-1 mother-to-child transmission

In endemic areas, prevention strategies may include modification or avoidance of breastfeeding when appropriate and feasible according to local recommendations.

HTLV-1 vs. HIV

HTLV-1

→ Retrovirus

→ Primarily infects T lymphocytes

→ Promotes T-cell proliferation/transformation

→ Adult T-cell leukemia/lymphoma

→ HAM/TSP

→ Often long latency

HIV

→ Retrovirus

→ Progressive destruction and dysfunction of CD4 T cells

→ Acquired immunodeficiency syndrome

→ Opportunistic infections and malignancies

Thus:

HTLV-1 tends to drive T-cell proliferation

whereas:

HIV primarily causes progressive immune deficiency

HTLV-1 vs. HTLV-2

HTLV-1

→ Strong established disease associations

→ ATLL

→ HAM/TSP

→ Infective dermatitis

→ Endemic clusters in Japan, Caribbean and other regions

HTLV-2

→ Frequently associated epidemiologically with injection drug use

→ No classic strongly established malignant syndrome comparable with HTLV-1

→ Generally lower recognized pathogenicity

High-Yield Clinical Pattern

Patient from an HTLV-1 endemic area

• ●

Adult T-cell malignancy

• ●

Hypercalcemia

→ Think HTLV-1 → Adult T-cell leukemia/lymphoma

Alternative High-Yield Pattern

Chronic progressive spastic weakness of both legs

• ●

Hyperreflexia

• ●

Bladder dysfunction

• ●

HTLV-1 exposure

→ Think HTLV-1–associated myelopathy / tropical spastic paraparesis

Exam Essentials

Viruses: HTLV-1 and HTLV-2

Family: Retroviridae

Genome: Positive-sense single-stranded RNA

Envelope: Present

Key enzyme: Reverse transcriptase

Replication: Proviral DNA integrates into host genome

Transmission: Sexual, blood exposure, shared needles, breastfeeding

HTLV-1 endemic regions: Southwestern Japan, Caribbean, parts of Africa and South America

HTLV-2 association: Injection drug use

Major HTLV-1 malignancy: Adult T-cell leukemia/lymphoma

Classic ATLL metabolic finding: Hypercalcemia

Classic ATLL blood cell: Flower cell

Major neurologic disease: HAM/TSP

Dermatologic association: HTLV-1–associated infective dermatitis

Parasitic association: Increased risk of severe/persistent Strongyloides infection

Diagnosis: Primarily serology, with confirmatory/molecular testing as needed

Treatment: Management of specific HTLV-associated disease; no routine curative antiviral eradication therapy

Prevention: Safer sex, blood/injection precautions, and prevention of mother-to-child transmission

Key clinical pearl: HTLV-1 is the retrovirus classically linked to two major examination syndromes: adult T-cell leukemia/lymphoma—often with hypercalcemia and “flower cells”—and a chronic progressive spastic paraparesis known as HAM/TSP. HTLV-2 is epidemiologically associated with injection drug use but has far weaker established disease associations.